Zobrazeno 1 - 10
of 703
pro vyhledávání: ''
Autor:
Jitsuo Usuda, Susumu Takeuchi, Kengo Nagashima, Noriko Motoi, Masahiro Seike, Jun Matsubayashi, Hideaki Shiraishi, Kazufumi Honda, Shun-ichi Watanabe, Rintaro Noro, Kaoru Kubota, Xue Meng, Tatsuya Inoue, Huang Wilber, Ayumi Kashiro, Tetsuya Okano, Yukihiro Yoshida, Shinobu Kunugi, Akihiko Gemma, Norihiko Ikeda
Publikováno v:
Cancer Science. 113:1002-1009
Although adjuvant tegafur/uracil (UFT) is recommended for patients with completely resected stage I non-small cell lung cancer (NSCLC) in Japan, only one-third of cases has received adjuvant chemotherapy according to real-world data. Therefore, robus
Autor:
Isamu Okamoto, Tatsuo Ohira, Nobuyuki Yamamoto, Hidehito Horinouchi, Toyoaki Hida, Shinji Atagi, Tatsuro Fukuhara, Miyako Satouchi, Kazuma Kishi, Shunichi Sugawara, Shi Rong Han, Hideo Saka, Victoria Ebiana, Katsuyuki Hotta, Keisuke Aoe, Kazuhiko Nakagawa, Hiroshi Sakai, Hiroaki Okamoto, Kazuo Noguchi, Kaname Nosaki, Atsushi Horiike, Shigeki Umemura, Toshiaki Takahashi, Takayasu Kurata, Nobuyuki Katakami, Akimasa Sekine
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death li
Autor:
Nicholas J Robert, Marley Boyd, Shrujal S. Baxi, Aaron B Cohen, Yanina Natanzon, Olga Tymejczyk, Mark Stewart, Laura Lasiter, Elizabeth Garrett-Mayer, Donna R. Rivera, Jeff Allen, Monika A Izano, Eric Hansen, Mackenzie Small, Jennifer B. Christian, Andrew J. Belli, Joseph Wagner, Janet L. Espirito, Connor Sweetnam
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:444-454
In prior work, Friends of Cancer Research convened multiple data partners to establish standardized definitions for oncology real-world end points derived from electronic health records (EHRs) and claims data. Here, we assessed the performance of rea
Autor:
Lucile Bussot, Simon Chevalier, Caroline Algrin, Anouk Emadali, Laurence David-Boudet, Christine Lefebvre, Cyril Fournier, Laurent Martin, Claire Vettier, O. Casasnovas, Remy Gressin, Caroline Chapusot, Mary Callanan, Edwige Col, Thierry Bonnefoix, Marie-Christine Jacob, Anne McLeer, Antonin Bouroumeau, Tatiana Raskovalova, Hervé Sartelet
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 7, Iss 6, Pp 604-615 (2021)
The Journal of Pathology: Clinical Research
The Journal of Pathology: Clinical Research
Diffuse large B‐cell lymphoma (DLBCL) is a clinically heterogeneous entity, in which the first‐line treatment currently consists of an immuno‐chemotherapy regimen (R‐CHOP). However, around 30% of patients will not respond or will relapse. Ove
Autor:
Qiong Lyu, Jian Zhang, Peng Luo, Ting Wei, Weimin Ding, Linlang Guo, Weiliang Zhu, Qiongyao Wang, Manming Cao
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7863-7876 (2021)
Cancer Medicine
Cancer Medicine
Background The majority of patients with small‐cell lung cancer (SCLC) show a good response in the early stages of treatment, but more than 90% of patients will develop drug resistance. Therefore, biomarkers are urgently needed to identify patients
Autor:
Lanfang Li, Xianhuo Wang, Jin He, Sicong Zhang, Bin Meng, Jing Zhao, Xiaoxing Su, Shiyong Zhou, Lihua Qiu, Hengqi Liu, Tingting Zhang, Huilai Zhang, Xiubao Ren, Zhengzi Qian, Haifei Zhou, Xianming Liu, Wenchen Gong
Publikováno v:
British Journal of Haematology. 196:617-628
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogenous malignancy, early identification of patients for relapse remains challenging. The potential to non-invasively monitor tumour evolutionary dynamics of DLBCL needs to be further established
Autor:
Wenqi Jiang, Li-Qin Ping, Qingqing Cai, Bing Bai, Xiaoxiao Wang, Jibin Li, Qixiang Rong, Jia-Ying Mao, Yan-Xia He, Haixia He, Cheng Huang, Yan Gao, Zhi Ming Li, He Huang, Huiqiang Huang
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 21, Pp 7650-7664 (2021)
Cancer Medicine, Vol 10, Iss 21, Pp 7650-7664 (2021)
Purpose Some studies have indicated that using 500 mg/m2 rituximab combined with CHOP‐14 may be beneficial for elderly men but not women with diffuse large B‐cell lymphoma (DLBCL). The purpose of this study was to investigate the potential benefi
Autor:
Xiaojing Zhang, Zhiqiang Meng, Shanzhi Gu, Shukui Qin, Zhendong Chen, Xiao Zhang, Linna Wang, Xinni Chen, Jianjun Zou, Ying Liu, Jianping Xiong, Zhenggang Ren
Publikováno v:
International Journal of Cancer. 149:1944-1954
Biliary tract cancer (BTC) is a highly malignant tumor with limited treatment options and poor prognosis. Our study aimed to evaluate camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced BTC. In this multicenter, open-l
Autor:
Stéphane Oudard, Brigitte Laguerre, Carole Helissey, Mathilde Cancel, Diego Teyssonneau, Pierre Emmanuel Brachet, Edouard Auclin, Constance Thibault, Philippe Barthélémy, Johanna Noel, Cedric Pobel, Denis Maillet, Elouen Boughalem
Publikováno v:
Cancer Medicine, Vol 10, Iss 18, Pp 6304-6309 (2021)
Cancer Medicine
Cancer Medicine
Introduction Cabazitaxel multiple rechallenges may be a treatment option in heavily pretreated patients with metastatic castration‐resistant prostate cancer (mCRPC) who had a good initial response to cabazitaxel and who are still fit to receive it.
Autor:
Mohammad Ghasemi, Andrew Goey, John Wilton, Wiam Bshara, Adrienne Groman, Renuka Iyer, Christos Fountzilas, Wen Wee Ma, Mateusz Opyrchal, Alex A. Adjei, Rachel Evans, Kristopher Attwood
Publikováno v:
Int J Cancer
In this phase I, dose-escalation study, we sought to determine the maximum tolerated dose (MTD) of the anaplastic lymphoma kinase/c-ROS oncogene 1 receptor (ALK/ROS1) inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients